The Promise and Challenges of Personalized Medicine in Hematologic Malignancies
Journal Title: Journal of Hematology & Thrombosis - Year 2015, Vol 1, Issue 2
Abstract
Personalized medicine is a rapidly emerging medical model that proposes individually customized healthcare to potentially increase the quality of clinical care and reduce health care costs. The key to the success of personalized medicine is development of diagnostics and therapeutics based upon molecular, genetic, epigenetic, pharmacogenomic and metabolic features of individual patients. Personalized medicine in oncology seeks to individualize cancer care and treatment decisions based upon features unique to each patient and each patient’s tumor. Medical decisions are then being tailored to the individual patient with the hope of providing improved quality-of-life and overall survival. Diagnostic testing is employed to select appropriate and optimal therapies based upon the context of each patient’s genetic content or other molecular or cellular tests. The concept of personalized medicine hopes to not only enhance the patient quality of life and survival but also to lower overall healthcare costs through early-detection, prevention, accurate risk assessments and more efficient health care delivery systems. However, personalized approaches in oncology face major, complex scientific and economic problems. Here, we discuss certain scientific and economic challenges that face the future of personalized medicine in the treatment of hematologic malignancies.
Authors and Affiliations
James J Driscoll
Keywords
Related Articles
- EP ID EP246516
- DOI 10.13188/2380-6842.1000007
- Views 157
- Downloads 0
The Evaluation of Cardiac Disorders and Systemic Hypertension in JAK2V617F Positive Patients at a Multicenter Institution
In this retrospective study; we evaluate cardiac disorders and systemic hypertension in JAK2 V617F positive patients. We identified 1000 patients in our hospital system that had been evaluated for JAK2 V617F mutation. Am...
Provisional Kuwaiti Children Hematology Reference Range
Introduction: Hematology reference ranges (HRR) in the third world countries usually based on results of measurements in advanced countries. Our HRR based on UK HRR since more than 5 decades. However, these parameters ar...
Residual Clot in Patients with Deep Vein Thrombosis and Pulmonary Embolism: Prognostic Implications
In order to assess whether there is discordance in the timing of thrombus resolution between deep vein thrombosis (DVT) and pulmonary embolism (PE), we analyzed current evidence from recent major literature, and evaluate...
osterior ReversibleEncephalopathy Syndrome after Paralytic Ileus during B-Cell Precursor Acute Lymphoblastic Leukemia Induction Therapy
A 9 year-old boy with B-cell precursor acute lymphoblastic leukemia developed paralytic ileus and severe abdominal pain during the induction therapy. In spite of fentanyl administration, abdominal pain could not be contr...
Differences in Circulating Endothelial Progenitor Cells among Childhood Cancer Survivors Treated with and without Radiation
Radiation during childhood cancer treatment increases the propensity to atherosclerotic cardiovascular disease among adult survivors of childhood cancer. This is thought to be mediated through the damage to the underlyin...